Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.73), $0.20 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $1.08 million versus the consensus estimate of $1.44 million.

“In the midst of these unprecedented times we are proud of the agile adaptation of our organization to successfully execute a virtual launch of CAPLYTA, a new treatment option for adult patients suffering from schizophrenia,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “Beyond our commercial efforts, we also continue to make progress in the advancement of our development programs, having completed patient enrollment in our Phase 3 clinical trial evaluating lumateperone as an adjunctive treatment in bipolar depression (Study 402) and clinical conduct in our proof-of-mechanism (Phase I/II) study evaluating ITI-214 in patients with heart failure.”

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.